Dr Matthew Ellington

Dr Ellington is a research active clinical scientist with broad experience in HCAI organisms. He has 15 years experience at the clinical / research interface in reference and frontline clinical laboratories with a specific and consistent focus on the molecular epidemiology of antimicrobial resistance among “ESKAPEE” pathogens. Dr Ellington’s expertise in investigating the factors underpinning antimicrobial resistance and supports his involvement with the European Committee on Antimicrobial Susceptibilty Testing (EUCAST) subcomittee on WGS for AST, as well as his recent appointment to the British Society for Antimicrobial Chemotherapy (BSAC) standing committee on antimicrobial susceptibility testing.